advertisement
advertisement

This company created the first-ever FDA-approved treatment for postpartum depression

Sage Therapeutics is taking a different approach to mood disorders, starting with one that affects more than 400,000 new mothers.

This company created the first-ever FDA-approved treatment for postpartum depression
[Illustration: Petra Eriksson]
THE WORLD’S 50 MOST INNOVATIVE COMPANIES
21 Sage Therapeutics
advertisement
advertisement

For the 400,000 women who suffer from postpartum depression (PPD) each year, treatment has been limited to psychotherapy and antidepressants that can take weeks to begin working. In March, Sage Therapeutics received FDA approval for Zulresso, the first specific treatment for PPD. Administered via an IV over 60 hours, Zulresso takes effect almost immediately. (The FDA doesn’t list any risks for infants, but Sage recommends patients consult a doctor before breastfeeding.)

advertisement

While traditional antidepressants are based on the idea that the underlying problem is depleted levels of neuro­transmitters (such as dopamine), Zulresso—Sage’s first approved therapy—targets the brain’s neuroreceptors. “It’s almost like resetting the nervous system,” says CEO Jeff Jonas. The company is applying the same approach to other conditions; Sage-217, an oral drug for major depressive disorder, won breakthrough designation from the FDA in 2018, and in clinical trials improved symptoms for most patients in a matter of days.

Read more about Fast Company’s Most Innovative Companies:

A version of this article appeared in the March/April 2020 issue of Fast Company magazine.